Continuing Pneumococcal Vaccination After Gavi Transition in Kenya at Full Price is Cost-effective and Could Save Thousands of Lives

This news release was originally published on EurekAlert. Below is an excerpt from the news release.

Co-led by the London School of Hygiene & Tropical Medicine and the KEMRI-Wellcome Trust Research Program, the Pneumococcal Conjugate Vaccine Impact Study estimated that continuing the vaccine beyond 2022 would prevent – in the first ten years – more than 100,000 children and adults from contracting pneumococcal disease and save the lives of 14,000 children and adults who would otherwise have died.

The cost per year of healthy life saved (US $153) was considerably less than Kenya’s annual gross domestic product (GDP) per person (US $1,790 in 2018), which meets – and far exceeds – the World Health Organization (WHO) GDP-related threshold for ‘very cost-effective’ health interventions.

The researchers say this study offers important evidence for policymakers at what is a crucial time for countries that have to decide whether to continue vaccine programs that have benefited from Gavi’s subsidy of the cost of vaccines once their economies grow and Gavi support diminishes.

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Call for resources: ThinkWell is inviting researchers to submit evidence on the cost of delivering immunization services

The Immunization Delivery Cost Catalogue (IDCC) is the most comprehensive, standardized global evidence on the cost of delivering vaccines, covering 317 unit costs from 68 studies published between 2005 and early 2019. The IDCC supports global and country immunization stakeholders in answering the question: “What are the unit costs of vaccine delivery across different low … Read More

New evidence on the costing the delivery of COVID-19 vaccines in Mozambique and the Philippines

ThinkWell has released two new reports on the cost of delivering COVID-19 vaccines in Mozambique and the Philippines, aiming to support governments and address the knowledge gap on the cost of these vaccination programs. In partnership with the Universidade Eduardo Mondlane and Ateneo de Manila University, ThinkWell conducted retrospective, bottom-up costing studies, as well as … Read More

Submissions Open for Special Issue of Vaccines on Estimating Vaccines’ Value and Impact

Estimating the value and public health impact of vaccines is critical to ensure evidence-based policy decision making in nearly all stages, from vaccine development to the introduction/implementation of vaccines in low-resource settings. To foster public health equity, as well as estimate value to local and national economies, concerted efforts are needed to increase the understanding … Read More